Gabapentin Tablet, Film Coated
Product Images NDC 43063-611

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 43063-611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063611 Label (43063611)

43063611 Label (43063611)
This is a description of a medication, Gabapentin, used to treat seizures and nerve pain. The bottle contains 90 tablets, each tablet containing 800 mg of Gabapentin USP. The tablet is oval / bisected in shape with markings 'ZE71' and white in color. The medicine should be taken a certain number of times a day, the dosage of which needs to be prescribed by a doctor. This bottle represents a LOT SAMPLE and it's REORDER number is 110272. The manufacturer of the medicine is 4 Pharmaceuticals from Oklahoma City, OK. The text also mentions organoleptic markings of the tablet but does not give any further details. The text advises patients to call their doctor in case of any side effects and report them to the FDA.*
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 01

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 01
This text appears to be a formula for calculating creatinine clearance (CLCr), a measure of kidney function that indicates how well a person's kidneys are filtering waste products from the blood. The formula takes into account the patient's weight in grams and their serum creatinine levels in milligrams per deciliter (mg/dL), with a correction factor of 0.35 for female patients. The meaning of "140-sge (g x weight (g)" is not clear, and appears to be a typographical error or an incomplete formula.*
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 02

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 02
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 03

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 03
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 04

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 04
This text describes a chart or graph showing the results of a study conducted over a period of several weeks. The study included a "Week Dose Titration Period" of three weeks, followed by a "4 Week Fixed Dose Period". The chart shows the effects of different doses of a drug (Gabapentin) compared to a placebo on an average pain score. The doses tested were 1800mg/day and 2400mg/day. The chart shows a decrease in pain score over time, with the lowest score achieved in week 4.*
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 05

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 05
The text seems to be a data table or chart representing percentages ranging from 0 to 100 with a few addition numerical values, followed by some text including currency values and a reference to "Study 2". There isn't enough context to provide a more detailed description or meaning behind the numbers shown.*
FDA Label Image

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 06

49957454 Bd5a 4d3c 85cf 6fe78aa2c11e 06

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.